General
Preferred name
IOVERSOL
Synonyms
MP-328 ()
Optiray ()
Optiray 300 ()
Optiray 320 ()
MP 328 ()
Optiray 350 ()
Optiray 160 ()
Optiray 240 ()
P&D ID
PD000855
CAS
8771-40-2
87771-40-2
Tags
available
drug
Approved by
FDA
First approval
1988
Drug Status
approved
Max Phase
Phase 4
Drug indication
Diagnostic Aid (radiopaque medium)
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Ioversol is excreted mainly through the kidneys following intravascular administration. Greater than 95% of the administered dose was excreted within the first 24 hours, with the peak urine concentration occurring in the first 2 hours after administration. Fecal elimination was negligible.;
TOXICITY Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ; Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events.; Caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.
INDICATION Optiray 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography. Optiray 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body, intravenous excretory urography, intravenous digital subtraction angiography and venography. Optiray 350 is indicated in children for angiocardiography.; Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.; Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography.; Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography.; Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.
Compound Sets
15
AdooQ Bioactive Compound Library
A13097
ChEMBL Approved Drugs
CHEMBL1200614
ChEMBL Drugs
CHEMBL1200614
DrugBank
DB09134
DrugBank Approved Drugs
DB09134
DrugCentral
1471
DrugCentral Approved Drugs
1471
DrugMatrix
MedChem Express Bioactive Compound Library
HY-B1410
NCATS Inxight Approved Drugs
N3RIB7X24K
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
lversol
The Spectrum Collection
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
806.86
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
8
Rotatable Bonds
12
Ring Count
1
Aromatic Ring Count
1
cLogP
-2.02
TPSA
199.89
Fraction CSP3
0.5
Chiral centers
2.0
Largest ring
6.0
QED
0.11
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Source data